Literature DB >> 3973257

Angiographic morphology and the pathogenesis of unstable angina pectoris.

J A Ambrose, S L Winters, A Stern, A Eng, L E Teichholz, R Gorlin, V Fuster.   

Abstract

In 110 patients with either stable or unstable angina, the morphology of coronary artery lesions was qualitatively assessed at angiography. Each obstruction reducing the luminal diameter of the vessel by 50% or greater was categorized into one of the following morphologic groups: concentric (symmetric narrowing); type I eccentric (asymmetric narrowing with smooth borders and a broad neck); type II eccentric (asymmetric with a narrow neck or irregular borders, or both); and multiple irregular coronary narrowings in series. For the entire group, type II eccentric lesions were significantly more frequent in the 63 patients with unstable angina (p less than 0.001), whereas concentric and type I eccentric lesions were seen more frequently in the 47 patients with stable angina (p less than 0.05). Type II eccentric lesions were also present in 29 of 41 arteries in patients with unstable angina compared with 4 of 25 arteries in those with stable angina (p less than 0.0001) in whom an "angina-producing" artery could be identified. Therefore, type II eccentric lesions are frequent in patients with unstable angina and probably represent ruptured atherosclerotic plaques or partially occlusive thrombi, or both. A temporary decrease in coronary perfusion secondary to these plaques with or without superimposed transient platelet thrombi or altered vasomotor tone may be responsible for chest pain in some of these patients with unstable angina.

Entities:  

Mesh:

Year:  1985        PMID: 3973257     DOI: 10.1016/s0735-1097(85)80384-3

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  72 in total

Review 1.  The pathophysiology of acute coronary syndromes.

Authors:  M J Davies
Journal:  Heart       Date:  2000-03       Impact factor: 5.994

2.  Pathobiology of Myocardial Necrosis.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

Review 3.  New developments in the detection of vulnerable plaque.

Authors:  M Naghavi; M Madjid; M R Khan; R M Mohammadi; J T Willerson; S W Casscells
Journal:  Curr Atheroscler Rep       Date:  2001-03       Impact factor: 5.113

4.  C-reactive protein is a marker for a complex culprit lesion anatomy in unstable angina.

Authors:  G V Moukarbel; M S Arnaout; S E Alam
Journal:  Clin Cardiol       Date:  2001-07       Impact factor: 2.882

Review 5.  Vulnerable plaque imaging-current techniques.

Authors:  K Chad Hilty; Daniel H Steinberg
Journal:  J Cardiovasc Transl Res       Date:  2009-01-14       Impact factor: 4.132

6.  Comparison of transradial and transfemoral artery approach for percutaneous coronary angiography and angioplasty: a retrospective seven-year experience from a north Indian center.

Authors:  Satyendra Tewari; Naveen Sharma; Aditya Kapoor; Sanjeev Kumar Syal; Sudeep Kumar; Naveen Garg; Pravin K Goel
Journal:  Indian Heart J       Date:  2013-07-12

Review 7.  Nitrates for unstable angina.

Authors:  U Thadani; L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

8.  Neopterin is associated with plaque inflammation and destabilisation in human coronary atherosclerotic lesions.

Authors:  T Adachi; T Naruko; A Itoh; R Komatsu; Y Abe; N Shirai; H Yamashita; S Ehara; M Nakagawa; C Kitabayashi; Y Ikura; M Ohsawa; M Yoshiyama; K Haze; M Ueda
Journal:  Heart       Date:  2007-06-17       Impact factor: 5.994

Review 9.  A new look at coronary angiograms: plaque morphology as a help to diagnosis and to evaluate outcome.

Authors:  J Lespérance; P Théroux; G Hudon; D Waters
Journal:  Int J Card Imaging       Date:  1994-06

10.  Early remodelling of coronary stenoses after thrombolytic treatment in patients with acute myocardial infarction.

Authors:  D Tousoulis; F Andreotti; D Hackett; A W Haider; A Maseri; G Davies
Journal:  Br Heart J       Date:  1995-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.